FDA Approves Tecentriq Plus Chemotherapy for Stage III Colon Cancer Adjuvant Treatment
Roche announced on October 9, 2026 that the FDA had approved Tecentriq plus chemotherapy for adjuvant treatment of stage III dMMR colon cancer based on the ATOMIC trial results.
Key Details
The phase III ATOMIC trial demonstrated a 50% reduction in hazard of disease recurrence or death with atezolizumab plus chemotherapy compared to chemotherapy alone.
Why It Matters
This approval establishes the first immunotherapy-based adjuvant treatment regimen for this colon cancer patient population in the United States.
Context
Roche is pursuing additional regulatory filings with the European Medicines Agency to expand access to this treatment outside the United States.
Source: OncoDaily. This article summarizes the linked reporting and distinguishes announced plans from demonstrated results.